Taewoong’s Niti-S™ range offers one of the most comprehensive portfolios in the field of biliary stenting, addressing both benign and malignant biliary strictures. The portfolio is structured to provide tailored solutions for a wide spectrum of clinical scenarios, from routine biliary drainage to complex anatomical challenges.
Routine Stents providing great clinical outcomes but at a cost effective rate
The portfolio includes both covered and uncovered self-expandable metal stents (SEMS) for benign and malignant strictures. The S, S Flare and D models are designed for general use, with features such as braided construction for optimal radial force and flexibility, and options for full or partial coverage to minimise tumour ingrowth and migration.
These stents have been implemented by sites across the country providing large savings, especially for high volume centres.
Specialty Stents
Specialty solutions are a hallmark of the Niti-S™ range. The LCD™ Y-shaped stent is designed for hilar obstructions, offering a unique “Y” configuration for complex biliary anatomy. The BUMPY™ stent, with its irregular cell sizes, is tailored for benign and pancreatic strictures, helping to reduce migration risk. Additionally, the range includes dedicated stents for post-transplant anastomotic strictures (KAFFES™).
The availability of both standard and specialty stents allows for optimal patient selection, which can further improve cost-effectiveness by reducing complications such as stent migration or occlusion.
Conclusion
Taewoong’s Niti-S™ biliary stent portfolio stands out for its breadth and depth, offering both standard and highly specialised solutions for a variety of biliary and pancreatic conditions. The inclusion of advanced delivery systems and stents tailored to complex anatomies or specific clinical challenges ensures that clinicians have access to the right tool for each patient. Supported by evidence for the cost-effectiveness of SEMS in biliary disease, this portfolio is well-positioned to deliver both clinical and economic value in practice.
Contact us for more information
5th – 6th February 2026: The 28th BSGAR Annual Meeting
17th March 2026: UK Biliary Intervention Study Day
23rd – 24th March 2026: Vascular Innovations and Technological Advancements Learning Symposium
7th May 2026: Liver Intervention Study Day
For more information, email Aquilant.newsletter@hc21.group or visit healthcare21.eu/
United Kingdom
Ireland